Healthtech funding in H1 2021
European Healthtech startup funding raised during H1 2021.
In H1 2021, 230 European Healthtech companies closed 232 funding rounds and raised €3.7B in equity funding (excluding debt and grants), up 54.2% versus H1 2020. Debt rounds added €190M. UK led by capital raised, and Accel was the most active investor. Data as of 20 Nov 2026.
Equity funding
€3.7B
+54.2% vs H1 2020 · excl. debt & grants · +€190M debt
Funding rounds
232
+14.3% vs H1 2020
Companies
230
Top country
UK
Rank among sectors
#5
5.9% of sector funding
Debt financing
€190M
4.9% of total
Top-10 round share
38.7%
of disclosed capital
Rounds ≥ €100M
7
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2021 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €597M | 34 |
| Feb | €476M | 27 |
| Mar | €497M | 34 |
| Apr | €818M | 37 |
| May | €864M | 51 |
| Jun | €660M | 49 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2021 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2021 | |
|---|---|
| UK | €1.4B |
| Germany | €562M |
| Israel | €472M |
| Sweden | €434M |
| Switzerland | €296M |
| Spain | €232M |
| Netherlands | €161M |
| Denmark | €153M |
Stage mix
by € raisedHealthtech — stage mix, H1 2021 — interactive chart.
Data table
| Healthtech — stage mix, H1 2021 | |
|---|---|
| Other | €1.3B |
| Series D+ | €709M |
| Series C | €650M |
| Series B | €559M |
| Series A | €374M |
| Debt | €190M |
| Seed | €109M |
| Growth/Late | €58M |
| Crowdfunding | €9.6M |
| Early VC | €2.3M |
| Pre-Seed | €655k |
| Grant | €401k |
Exits & M&A
15 Acquisition · 2 IPO17 exits · €1.4B disclosed.
| Arvelle Therapeutics | Acquisition | Jan 2021 | €784M |
| Babylon | IPO | Jun 2021 | €470M |
| Ginolis | Acquisition | Feb 2021 | €70M |
| MatTek | Acquisition | Mar 2021 | €57M |
Top deals
largest disclosed rounds in H1 2021| Company | Stage | Date | Amount |
|---|---|---|---|
| Kry | Series D+ | Apr 2021 | €262M |
| Oxford Nanopore Technologies | Other | May 2021 | €225M |
| Quanta | Series D+ | Jun 2021 | €205M |
| Immunocore | Debt | Feb 2021 | €190M |
| Atai Life Sciences | Series D+ | Mar 2021 | €131M |
| IO Biotech | Series B | Jan 2021 | €127M |
| Huma | Series C | May 2021 | €107M |
| CeQur | Series C | Apr 2021 | €97M |
| Melio | Series C | Jan 2021 | €90M |
| Evox Therapeutics | Series C | Feb 2021 | €80M |
| Monte Rosa | Series C | Mar 2021 | €80M |
| Lumicks | Other | Apr 2021 | €77M |
| Ada health | Series B | May 2021 | €74M |
| Alchemab Therapeutics | Series A | Apr 2021 | €69M |
| Kaia Health | Series D+ | Apr 2021 | €62M |
Top investors
most active in H1 2021, by deal count- Accel4 deals
- Octopus Ventures4 deals
- AlbionVC3 deals
- Almi Invest3 deals
- btov Partners3 deals
- Foresight Group3 deals
- IBB Ventures3 deals
- IDInvest Partners3 deals
- Index Ventures3 deals
- Leaps by Bayer3 deals